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ABSTRACT
Objective: The objective of this study was to describe the prevalence and molecular characterization of blaCTX-M-15-producing pathogenic Gram-negative 
bacteria from various clinical samples isolated from clinically suspected patients.
Methods: In this study, clinical samples of urine, stool, sputum, and pus were collected from 244 patients with nosocomial infections. The phenotypic 
identification of extended-spectrum β-lactamases (ESBL) was confirmed by double-disk synergy test and combined disk diffusion test. In vitro, the 
susceptibility pattern of antimicrobial agents against pathogenic isolates was performed by Kirby–Bauer disk diffusion method. The identification of 
blaCTX-M-15-producing Escherichia coli was assessed by polymerase chain reaction method.
Results: The frequency of ESBL-producing pathogenic bacteria from screened was 6 (46.15%). In vitro, susceptibility to pathogenic bacteria showed 
that the majority of isolates were highly susceptible to amoxicillin-clavulanic acid (97.87%), ofloxacin (93.33%), and Pseudomonas aeruginosa showed 
100% sensitive to ceftazidime, cefotaxime, cefixime, cefoperazone, and meropenem (92.30%). The rates of resistance to other antibiotics varied from 
<26.66%. Among six tested isolates, only one E. coli isolates showed blaCTX-M-15 gene.
Conclusion: Due to the increase of E. coli with multiple ESBL genes, continuous surveillance should be needed in clinical field to use of appropriate 
antibiotics and the control of infections.
Keywords: CTX-M-15 gene, Clinical samples, Extended-spectrum β-lactamases, Escherichia coli, Multidrug resistance.
INTRODUCTION
Extended-spectrum β-lactamases (ESBLs) are enzymes produced 
by pathogens belonging to Enterobacteriaceae, most commonly 
Escherichia coli and Klebsiella pneumoniae [1]. The most common 
bacterial infections in humans are the urinary tract infections (UTIs), 
both in the community and the hospitals. In India, the incidence of 
UTI is about 50,000/million persons per year. Beta-lactam (β-lactam) 
antimicrobials are characterized by having a four-membered cyclic 
amide (β-lactam ring) as part of their chemical structure. A β-lactam 
ring is a four-membered lactam (a lactam is a cyclic amide). It is named 
as such because the nitrogen atom is attached to the β-carbon atom 
relative to the carbonyl [2].
ESBLs are known for their ability to hydrolyze β-lactam antibiotics 
such as penicillins, cephalosporins, and monobactams, resulting 
in antimicrobial therapy failure [3]. The CTX-M enzymes are the 
predominant type of ESBL found in many regions of the world, including 
Asia, South America, Europe, and Africa [4]. In the past 5–10 years, the 
incidence of infections caused by Enterobacteriaceae producing ESBL 
has increased rapidly mainly attributed to the successful distribution 
of CTX-M enzymes between E. coli causing urinary tract and bacteremic 
infections [5]. CTX-M-type β-lactamases (CTX-Ms) are broad-spectrum 
β-lactamases derived from the chromosomally encoded β-lactamases 
of Kluyvera sp. So far, >70 CTX-M types have been isolated and have 
been divided into five clusters because of amino acid sequence: 
CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25. Native CTX-
Ms are cefotaximases that usually hydrolyze cefotaxime rather than 
ceftazidime. However, point mutations can extend their target spectrum 
to ceftazidime. Thus, CTX-M-15 and CTX-M-27 are derived by a single 
Asp240Gly substitution from CTX-M-3 and CTX-M-14, respectively [6].
Infections by ESBL-producing organisms are a worldwide problem. 
Extensive use of broad-spectrum antibiotics in hospitals has 
contributed to an increased carriage of Klebsiella, and subsequently, 
the development of multidrug-resistant strains that produce ESBL [7]. 
Critical care units provide a favorable environment for the antimicrobial-
resistant organisms to disseminate. There is recent increase in number 
of ESBL producers because of the emergence of CTX-M beta-lactamases 
produced by Enterobacteriaceae. They colonize the intestinal flora and 
spread with greater intensity in the community and hospital. This study 
was designed to assess the prevalence and molecular characterization 
of CTX-M-15 (ESBL)-producing pathogenic Gram-negative bacteria 
(GNB) from various clinical samples.
MATERIALS AND METHODS
Study design
The study was designed to investigate the prevalence and molecular 
characterization of CTX-M-15-producing pathogenic GNB in various 
clinical samples. The collection of clinical sample and identification of 
isolates were carried out in Vivekanandha Medical Care Hospital (VMCH), 
Elayampalayam, Tiruchengode, Tamil Nadu (India), to purpose of 
microbiological culture and sensitivity test. In our study, the clinical isolates 
and its secondary data were obtained from VMCH, and farther process was 
carried out at the Department of Microbiology in Vivekanandha College of 
Arts and Science for Women, Elayampalayam, Tiruchengode, Tamil Nadu 
(India), during the period of March 2016–July 2016.
Inclusion and exclusion criteria
While collecting clinical samples, those clinically suspected subjects 
who have not taken antibiotic therapy had been included in the study 
and if the suspected cases that have undergone therapy were excluded 
from the study.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i10.25111
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Identification of pathogenic GNB
The obtained isolates were inoculated into Nutrient agar and 
MacConkey agar and incubated at 37°C for 24 h. Then, isolated organism 
was identified according to the Bergey’s manual of determinative 
bacteriology. The confirmed isolates of E. coli, K. pneumoniae, and 
Pseudomonas aeruginosa were maintained at 4°C on nutrient agar 
slants for further use.
Antibiotic susceptibility test
Susceptibility testing of bacterial isolates was performed using the disc 
diffusion method as described by the Clinical and Laboratory Standards 
Institute (CLSI) [8]. Antimicrobial discs used imipenem (10 mcg), 
meropenem (10 mcg), ceftazidime (30 mcg), cefotaxime (30 mcg), 
cefixime (5 mcg), cefoperazone (75 mcg), amoxyclav (amoxicillin/
clavulanic acid) (30/10 mcg), aztreonam (30 mcg), amikacin (30 mcg), 
norfloxacin (5 mcg), ofloxacin (30 mcg), and nitrofurantoin (300 mcg). 
The diameter of the zone of inhibition for each antibiotic was measured 
and interpreted as resistant, sensitive. The antibiotic disks used were 
obtained from Hi-Media Pvt. Ltd., Mumbai, India.
Screening of multidrug-resistant (MDR) isolates
The antibiogram patterns of the GNB were analyzed. The isolates which 
were showed resistant to more than three classes of antibiotics are 
considered as a multidrug resistance isolates [9].
Screening test for ESBLs
The isolates were tested for their susceptibility to the third-generation 
cephalosporins (3 GCs), for example, ceftazidime (30 μg), cefotaxime 
(30 μg), and ceftriaxone (30 μg) using the standard disc diffusion 
method as recommended by the CLSI. If a zone diameter of <22 mm 
for ceftazidime, <27 mm for cefotaxime, and <25 mm for ceftriaxone 
was recorded, the strain was considered to be “suspicious for ESBL 
production” [10]. Only those isolates which were resistant to one of 
the 3 GCs were selected for the study and were processed for ESBL 
production.
Phenotypic confirmatory tests for ESBLs
The presence of ESBL between selected isolates positive on screening 
was confirmed using following two methods on in vitro condition.
Combination disc method (CDM)
This test requires the use of a third-generation cephalosporin antibiotic 
disc alone and in combination with tazobactam. In this study, a disk 
of ceftazidime (30 μg) alone and a disk of ceftazidime+tazobactam 
(30/10 μg) were used. Both the disks were placed at least 25 mm apart, 
center-to-center, on a lawn culture of the test isolate on Mueller-Hinton 
agar (MHA) plate and incubated overnight at 37°C. Difference in zone 
diameters with and without tazobactam was measured [10].
Interpretation
When there is an increase of ≥5 mm in inhibition zone diameter around 
combination disk of ceftazidime + tazobactam versus the inhibition zone 
diameter around ceftazidime disk alone, it confirms ESBL production.
Double-disc synergy test (DDST)
In DDST, synergy was determined among a disc Augmentin (20 mg 
amoxicillin + 10 μg clavulanic acid) and 30 mg of disc of cefotaxime and 
ceftazidime antibiotics placed at a distance of 15 mm apart from the 
center disc on the surface of culture of the resistant isolate under test 
on MHA. The test organisms were considered to produce ESBL if the 
zone size around the test antibiotic disc was more than 5 mm and above 
toward the augmentin disc. This increase occurs because the clavulanic 
acid present in the Augmentin disc inactivates ESBL enzymes produced 
by the test organism [11].
Detection of CTX-M
Aztreonam, ceftazidime, cefotaxime, and cefotaxime-clavulanic acid, 
and ceftriaxone are used to detect CTX-M type ESBL. CTX-M strains 
are resistant to cefotaxime and sensitive to cefotaxime plus clavulanic 
acid. The antibiotics were placed on Muller-Hinton agar (MHA) plate. 
After incubating overnight at 37°C, more than 5 mm increase in the 
zone diameter for combination with clavulanic acid was interpreted as 
positive for CTX-M production.
Isolation of genomic DNA by phenol, chloroform method
The positive isolates were used for the isolation of genomic DNA to 
detect the CTX-M-15 (ESBL) gene by molecular method. Single colony 
of the culture of GNB was inoculated into a conical flask containing 
50 ml of sterile LB broth (without antibiotic). The culture is 
incubated overnight at 37°C. After incubation, transfer 2 ml of culture 
into Eppendorf tube and centrifuged at 10,000 rpm for 5 min at 4°C. 
Discard the supernatants gently by aspiration. The pellet obtained 
must be suspected in 1 ml of sodium chloride buffer. Add 250 µl 
of 10% sodium dodecyl sulfate and mix well. The mixture must be 
incubated in water bath at 60°C for 15 min. Cool at room temperature 
and to this mixture adds 500 µl of phenol, chloroform in the ratio 1:2 
centrifuge at 10,000 rpm for 5 min at 4°C. Transfer the supernatant 
in to a fresh eppendorf tube. Equal volume of ice-cold 95% ethanol 
must add to the supernatant. The reaction mixture must be incubated 
in ice for 15–30 min (if precipitation is delayed). The DNA can be 
spooled with the help of a tip and transferred into fresh tube and 
centrifuged at maximum speed for 5 min and the supernatant can be 
discarded. The DNA pellet must be washed with 90% ethanol. This 
step must be repeated once again, final wash was done with 75% 
ethanol and air dried for 15 min. Dissolve the DNA pellet in 20 µl 
TE buffer. Add 10 µl of tracking dye in to 20 µl of DNA sample, mix 
it well, and load the wells (0.7% agarose). Connect electrophoresis 
apparatus to power pack and perform electrophoresis at 50 V using 
1X TBE as the running buffer. Visualize the DNA bands under UV-
transilluminator.
Molecular identification of blaCTX-M-15 (ESBL) gene by polymerase 
chain reaction (PCR) technique
The isolated DNA was subjected to detect the CTX-M-15 (ESBL) gene 
using specific primers (Table 1).
PCR technique has been used to amplify genes encoding the 
CTX-M-15 β-lactamases from genomic DNA of greatest resistant 
pattern of E. coli strain. DNA amplification was performed in an 
Eppendorf thermal cycler (Roche Co., Germany) in a final volume of 
25 µL containing 2.5 µL of ×10 PCR buffer, 2.5 µM of dNTP mix, 10 
µM of each primer, 0.2 U of Taq DNA polymerase, and 0.5 µL of the 
template DNA. PCR conditions for the CTX-M gene composed an initial 
denaturation step for 5 min at 94°C, followed by 34 cycles of 94°C 
for 45 s, 55°C for 45 seconds, and 72°C for 1 min, with extension at 
72°C for 5 min. The primers used in the above-mentioned reactions 
can amplify the DNA fragments correspond with 451 base pair (bp) 
of CTX-M-15 gene. The PCR products were loaded on a 1% (W/V) 
agarose gel with 0.5 µg/ml ethidium bromide and were analyzed by 
gel electrophoresis method.
RESULTS
The data regarding this study and other background variables such 
as age, sex, antibiogram resistance pattern, and enzyme production 
were elicited from the secondary data obtained from the hospital. The 
collected samples and information were subjected to statistical analyses 
to explicate extensively the prevalence of extended β-lactamase 
products among the isolates in the study area. The study is based on the 
sample of 244 subjects (Fig. 1).
Table 1: Sequence of the primers used to detect the CTX-M-15 
gene
Primers Sequence Amplicon size
Forward 5’- AAA AAT CAC TGC GCC AGT TC-3’ 415bp
Reverse 5’- AGC TTA TTC ATC GCC ACG TT- 3’
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Isolation and identification of pathogenic GNB
A total of 244 various clinical samples were streaked on nutrient 
agar, HiCrome UTI agar, and MacConkey agar. The E. coli produced 
pink to purple color and K. pneumoniae produced blue color mucoid 
colonies on HiCrome UTI agar (Fig. 2). P. aeruginosa produced green 
color pigmentation on nutrient agar (Fig. 3). Of the 244 samples, 
114 samples showed positive for growth and 130 for no growth. From 
positive growth, 88 samples showed positive for GNB and 26 samples 
showed other organisms such as Gram-positive. The isolated colonies 
were identified according to the Bergey’s manual of determinative 
bacteriology (Tables 2 and 3).
Antibiotic susceptibility test
A total of 12 antibiotics of seven classes were used against E. coli, 
K. pneumoniae, and P. aeruginosa. More than 80% of the isolates were 
sensitive for imipenem, cefixime, amoxyclav, aztreonam, and ofloxacin. 
Specifically, P. aeruginosa exhibited <10% resistance to all antibiotics 
and 100% sensitive to ceftazidime, cefotaxime, cefixime, cefoperazone, 
amoxyclav, aztreonam, and ofloxacin (Table 4).
Screening of MDR and ESBL-producing pathogenic GNB
Of the 88 isolates, 18 (66.66%) isolates of E. coli and 6 (22.22%) 
isolates of K. pneumoniae were screened to be MDR strains in urine 
samples. 1 (3.70%) K. pneumoniae isolate in pus and 2 (7.40 %) 
isolates of K. pneumoniae in sputum were screened as MDR. In ESBL 
screening test, 8 (61.53%) E. coli, 4 (30.76%) K. pneumoniae from 
urine, and 1 (7.69%) K. pneumoniae from pus sample were positive 
for ESBL production. All the isolates in stool showed negative for both 
MDR and ESBL (Table 5).
Multidrug resistance pattern of GNB clinical isolates
Of the 88 GNB isolates, the drug resistance pattern shows that among 
the 37 MDR isolates, 13 (35.1%) show resistant to 1 drug, 7 (18.9%) 
to 2 drugs, 4 (10.8%) to 3 drugs, 1 (2.70%) to 4 drugs, 2 (5.4%) to 
5 drugs, 1 (2.70%) to 6 drugs, 1 (2.70%) to 7 drugs, 3 (8.10%) to 8 
drugs, 4 (10.8%) to 9 drugs, and 1 (2.70%) to 10 drugs. Of the resistant 
organisms, 3 (8.10%) show resistant to 8 drugs, 4 (10.8%) show 
resistant to 9 drugs, and 1 (2.70%) shows resistant to 10 drugs (Fig. 4).
Phenotypic confirmation of ESBL producers
A total of 13 ESBL isolates screened were subjected to the phenotypic 
confirmatory methods. In this, 5 (83.33%) isolates of E. coli and 
1 (16.6%) isolate of K. pneumoniae showed strongly positive for ESBL 
production in both the methods and seven isolates were identified as 
non-ESBL producers (Table 6 and Figs. 5 and 6).
Age- and sex-wise prevalence of ESBL-producing GNB
The study subjects were classified into three age groups, one isolate of 
K. pneumoniae was found in age group among 20–40 followed by 41–60 
for one isolates of E. coli and four E. coli in the age group of 61–80 years. 
In sex, males are the more prevalent than female that is distributed 
in three isolates of E. coli in male and two in female and one isolates 
K. pneumoniae were from male (Table 7).
Fig. 1: Collection of clinical samples
Fig. 2: Escherichia coli and Klebsiella pneumoniae on urinary tract 
infections agar
Fig. 3: Pseudomonas aeruginosa on nutrient agar
Table 2: Distribution of pathogenic GNB growth in clinical 
samples
Clinical samples (n=244) Growth GNB Others
Urine (n=126) 72 61 11
Stool (n=25) 4 3 1
Sputum (n=42) 17 10 7
Pus (n=51) 21 14 7
Total 114 88 26
GNB: Gram-negative bacteria
Table 3: Frequency of pathogenic GNB isolates
Clinical samples n (%)
E. coli K. pneumoniae P. aeruginosa
Urine (n=126) 44 (93.61) 9 (60) 8 (30.76)
Stool (n=25) 3 (6.38) 0 (0) 0 (0)
Sputum (n=42) 0 (0) 4 (26.66) 6 (23.07)
Pus (n=51) 0 (0) 2 (13.33) 12 (46.15)
Total ( n=244) 47 (99.99) 15 (99.99) 26 (99.98)
E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, 
P. aeruginosa: Pseudomonas aeruginosa, GNB: Gram-negative bacteria
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Age- and sex-wise prevalence of pathogenic GNB
The age-wise distribution of pathogenic GNB is shown in Fig. 7. The age 
group was classified into five. The age among 61–80 was mostly infected 
with E. coli 30 (63.82%) followed by K. pneumoniae 8 (53.33%) and 
P. aeruginosa 12 (46.15%), respectively. The prevalence of pathogenic 
GNB was more between the male as compared to female. Between the 
total of 88 isolates, 49 (55.68%) were from male and 39 (44.31%) from 
female (Fig. 8).
Molecular characterization of blaCTX-M-15-producing pathogenic GNB
In PCR experiment, totally six isolates were subjected to detect the 
bla CTX-M-15 gene. Among that, only one isolate of E. coli gave positive PCR 
result for CTX-M-15 gene (Fig. 9).
DISCUSSION
The increase of resistance to antibiotics and the existence of multidrug 
resistant in ESBL producers have become an emerging public health 
Table 4: Antibiotic resistance and sensitivity profile of E. coli, K. pneumoniae, and P. aeruginosa
Antimicrobial agent (mcg) Symbol E. coli (47) K. pneumoniae (15) P. aeruginosa (26)
Sensitive (%) Resistant (%) Sensitive (%) Resistant (%) Sensitive (%) Resistant (%)
Beta-lactam drugs 
Carbapenem
Imipenem (10 mcg) IPM 38 (80.85) 9 (19.14) 13 (86.66) 2 (13.33) 25 (96.15) 1 (3.84)
Meropenem (10 mcg) MRP 41 (87.2) 6 (12.7) 11 (73.33) 4 (26.66) 24 (92.30) 2 (7.69)
Cephems
Ceftazidime (30 mcg) CAZ 43 (91.48) 4 (8.51) 11 (73.3) 4 (26.66) 26 (100) -
Cefotaxime (30 mcg) CTX 44 (93.61) 3 (6.38) 10 (66.66) 5 (33.33) 26 (100) -
Cefixime (5 mcg) CFM 41 (87.23) 6 (12.76) 13 (86.66) 2 (13.33) 26 (100)  -




(amoxicillin/clavulanic acid)  
(30/10 mcg)
AMC 46 (97.87) 1 (2.12) 15 (100) - 26 (100) -
Monobactam
Aztreonam (30 mcg) AT 40 (85.10) 7 (14.89) 13 (86.66) 2 (13.33) 24 (92.30) 2 (7.69)
Aminoglycosides
Amikacin (30 mcg) AK 35 (74.46) 12 (25.53) 12 (80) 3 (20) 23 (88.46) 3 (11.53)
Fluoroquinolones
Norfloxacin (5 mcg) NX 37 (78.72) 10 (21.27) 13 (86.66) 2 (13.33) 24 (92.30) 2 (7.69)
Ofloxacin (5 mcg) OF 40 (85.10) 7 (14.89) 14 (93.33) 1 (6.66) 23 (88.46) 3 (11.53)
Nitrofuran
Nitrofurantoin (300 mcg) NIT 36 (76.59) 11 (23.40) 13 (86.66) 2 (13.33) 26 (100) -
E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, P. aeruginosa: Pseudomonas aeruginosa
Table 5: Screening of MDR and ESBL-producing pathogenic GNB
Clinical samples Total isolates GNB Screened MDR (%) Screened ESBL (%)
Urine (n=126) GNB=61 E. coli (44) 18 (66.66) 8 (61.53)
MDR=24 K. pneumoniae (9) 6 (22.22) 4 (30.76)
ESBL=12 P. aeruginosa (8) - -
Stool (n=25) GNB=3 E. coli (3) - -
MDR=0 K. pneumoniae (0) - -
ESBL=0 P. aeruginosa (0) - -
Pus (n=51) GNB=14 E. coli (0) - -
MDR=1 K. pneumoniae (2) 1 ( 3.70) 1 (7.69)
ESBL=1 P. aeruginosa (12) - -
Sputum (n=42) GNB=10 E. coli (0) - -
MDR=2 K. pneumoniae (4) 2 (7.40) -
ESBL=0 P. aeruginosa (6) - -
Total 27 (99.98) 13 (99.98)
GNB: Gram-negative bacteria, MDR: Multidrug resistance, ESBL: Extended-spectrum beta lactamase, E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, 
P. aeruginosa: Pseudomonas aeruginosa
Table 6: Phenotypic confirmation of ESBL producers
GNB isolates Phenotypic confirmatory methods
ESBL screened by disc diffusion method (%) CDM and DDST
ESBL (%) Non-ESBL (%)
E. coli (n=47) 8 (61.53) 5 (83.33) 3 (42.85)
K. pneumoniae (n=15) 5 (38.46) 1 (16.6) 4 (57.14)
P. aeruginosa (n=26) - 0 (0) 0 (0)
Total ( n=88) 13 (14.77%) 6 (46.15%) 7 (53.84%)
E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, P. aeruginosa: Pseudomonas aeruginosa, DDST: Double-disc synergy test, CDM: Combination disc method, 
ESBL: Extended-spectrum β-lactamases
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problem due to the clinical failure of empirical treatment protocols [12]. 
Although the mechanism of resistance between ESBL-producing E. 
coli may be varied, it has been documented that the most common 
mechanism of resistance to β-lactam antibiotics in E. coli isolates is 
beta-lactamase production.
In a study, there were 100 specimens of E. coli isolated from the urine 
samples and their resistance to antibiotics penicillin, amoxicillin, 
cephalexin, ceftriaxone, and imipenem was 100%, 100%, 43%, 46%, 
and 2%, respectively [13]. These results exhibited a high frequency of 
resistance between E. coli isolates to the common antibiotics, especially 
penicillin, amoxicillin, and cephalosporins such as cefotaxime and 
ceftazidime which are used routinely in the treatment of UTIs. According 
to another study that was conducted by the European Antibiotic 
Resistance Surveillance System in 2006, continual increase of resistant 
to the third-generation cephalosporins has been reported in over 800 
laboratories from 31 countries [14]. Overall, due to indiscriminate use 
of antibiotics and low standard of personal and community hygiene, 
the percentage of E. coli resistance to chloramphenicol, ampicillin, 
tetracycline, aminoglycosides, and sulfonamides in developing 
Table 7: Age- and sex-wise prevalence of ESBL producers
Age Sex
Age group ESBL producer ESBL producer
E. coli K. pneumoniae Gender E. coli K. pneumoniae
20–40 0 (0) 1 Male 3 1
41–60 1 0 (0) Female 2 0
61–80 4 0 (0)
E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, ESBL: Extended-spectrum β-lactamases
Fig. 4: Multidrug resistance pattern of Gram-negative pathogenic 
bacteria
Fig. 5: Combination disc method
Fig. 6: Double-disc synergy test
Fig. 7: Age-wise prevalence of pathogenic Gram-negative bacteria
Fig. 8: Sex-wise prevalence of pathogenic Gram-negative bacteria
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countries is higher than industrialized countries [15]. Compare to 
above study, the contrast results were observed >80% of sensitive was 
observed for imipenem, cefixime, amoxyclav, aztreonam, and ofloxacin. 
Specifically, P. aeruginosa exhibited <10% of resistant to all antibiotics 
and 100% sensitive to ceftazidime, cefotaxime, cefixime, cefoperazone, 
amoxyclav, aztreonam, and ofloxacin.
In our study, the most age group infected with ESBL-producing E. coli 
and K. pneumoniae was between 41 and 60 and 61–80. Our findings, 
regarding the age of the patients, are in accordance with recent 
data that state aging is a risk factor for beta-lactamase-mediated 
resistance in patients infected with enterobacteria. In recent 
years, ESBL-producing E. coli isolates have increased frequently 
in different parts of the world, particularly Asia [16]. In our study, 
the ESBL-producing pathogenic GNB was 46.15% to E. coli and 
K. pneumoniae collected over a period of 6 months. The prevalence 
of ESBL-producing strains varies with geographic region, country 
studied, and institution. In this respect, several studies expressed 
that the ESBL production is much less frequent in Europe than in 
Latin America and Asia, and they are even less frequent in the Pacific 
than in North America [17]. This may be due to the differences in the 
type of samples, in the time of sample’s collection, consumption of 
antibiotics, and differences.
The rate of resistance to multiple antibiotics between pathogenic 
isolates is usually common due to carrying multi-resistant genes 
and plasmids. In the present study, our isolates were resistant not 
only to beta-lactam but also to different antibiotic families including 
monobactam, nitrofuran, fluoroquinolones and aminoglycosides, and 
carbapenem. This obtained resistance pattern was similar to those 
commonly described in other studies [18]. As previous noted, the 
most prevalent types of ESBLs are SHV-, TEM-, and CTX-M-type that 
arise mainly due to mutations in beta-lactamase genes. We detected a 
beta-lactamase among the E. coli isolates of CTX-M-15 gene expresser. 
Although TEM and SHV variants were the most common ESBLs 
during the past decade, newly CTX-M beta-lactamases have emerged 
as prevalent ESBL worldwide type compared to the TEM and SHV 
genotypes [19].
The relation of pathogenic and ESBL-producing Enterobacteriaceae 
with respect to age and gender and reported more ESBL-positive 
isolates in males (65.33%) than females (34.67%) [20]. Similar 
findings were observed in the present study. Most of the medical 
laboratories in our country do not screen ESBL production. 
Appropriate antibiotic therapy and detection of ESBLs in laboratories 
Fig. 9: Detection of gene encoding blaCTX-M-15 in extended-spectrum 
β-lactamases-producing Escherichia coli by polymerase chain 
reaction. Lane 1 - 1Kb DNA ladder, Lane 2 - CTX-M-15 positive for 
Escherichia coli
need to be carried out to prevent dissemination of these organisms and 
resistance genes. Our study reports showed that E. coli were a most 
ESBL producers which nearly correlate with a study conducted by 
Sandhiya et al. [21]. Between the wound/swab isolates, Pseudomonas 
was the predominant GNB followed by Klebsiella and E. coli. This 
result is in contrast to Divyashanthi et al. [22] where Klebsiella was 
the predominant GNB.
CONCLUSION
We analyzed the antimicrobial drug susceptibility and molecular 
detection of CTX-M-15 gene in clinical samples. The prevalence 
rates of the resistant strains have dramatically increased. These 
findings suggest that the cefotaxime-resistant isolates are genetically 
closely related and harbor a chromosome carrying the blaCTX-M-15 
gene and posing an urgent threat to public health. Therefore, more 
comprehensive surveillance is required to prevent farther spread of 
resistant strains.
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